Evidence map›Paper›PMID 39731207›Full record

ArticleTransactions of the Royal Society of Tropical Medicine and Hygiene2025

Risk perception and mpox vaccine acceptability among people living with HIV in northern Nigeria.

Zubairu Iliyasu, Aminatu A Kwaku, Nafisa S Nass, Amina A Umar, Taiwo G Amole, Hadiza M Abdullahi, Fatimah I Tsiga-Ahmed, Abubakar M Jibo, Brittany R Fontana, Hamisu M Salihu and 1 more

Abstract read
In one paragraph

Article in Transactions of the Royal Society of Tropical Medicine and Hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zubairu IliyasuDepartment of Community Medicine, Bayero University, Kano, Nigeria.
Aminatu A KwakuDepartment of Community Medicine, Bayero University, Kano, Nigeria.
Nafisa S NassDepartment of Community Medicine, Bayero University, Kano, Nigeria.
Amina A UmarDepartment of Community Medicine, Bayero University, Kano, Nigeria.
Taiwo G AmoleDepartment of Community Medicine, Bayero University, Kano, Nigeria.
Hadiza M AbdullahiDepartment of Community Medicine, Bayero University, Kano, Nigeria.
Fatimah I Tsiga-AhmedDepartment of Community Medicine, Bayero University, Kano, Nigeria.
Abubakar M JiboDepartment of Community Medicine, Bayero University, Kano, Nigeria.
Brittany R FontanaSchool of Medicine, Meharry Medical College, Nashville, TN 37208, USA.
Hamisu M SalihuKano Independent Research Centre Trust, Kano, Nigeria.
Muktar H AliyuDepartment of Health Policy and Vanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, TN 37203, USA.ORCID 0000-0001-9504-4679

Funding

Vanderbilt-Nigeria Building Research Capacity in HIV and Non-communicable Diseases (NCDs) (V-BRCH) 2D43TW011544 · FIC · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Aishatu Adamu, Muktar Hassan Aliyu · 2020 to 2026
$2.1M
FIC NIH HHS D43 TW011544NIAAA NIH HHSNIH HHS 1D43TW011544U.S. Department of Health and Human Services
6 · The paper itself

Abstract

backgroundThere is a dearth of information regarding mpox risk perception and vaccine acceptance among people living with human immunodeficiency virus (HIV), especially in countries with a dual burden of HIV and mpox, such as Nigeria.

methodsWe used an explanatory mixed methods design and structured questionnaires administered to a clinic-based sample of people living with HIV (n=430), followed by in-depth interviews with a purposive subsample (n=20). Data were analysed using binary logistic regression and the framework approach.

resultsMore than one-third (38.1% [n=164]) of the respondents self-perceived a high risk of mpox and 64.4% (n=277) indicated a willingness to receive the vaccine. Willingness to accept the mpox vaccine was positively associated with male sex, older age, non-Muslim faith, unmarried status, post-secondary education and current civil service employment. The odds of accepting the mpox vaccine was also higher among respondents who perceived mpox as a serious disease (adjusted odds ratio [aOR] 1.41 [95% confidence interval {CI} 1.12 to 2.35]), self-assessed a higher risk (aOR 1.66 [95% CI 1.19 to 3.06]) and were concerned about contracting the disease (aOR 1.78 [95% CI 1.12 to 3.94]). Reasons for hesitancy included anxiety about vaccine-antiretroviral drug interactions, low risk perception, perceived protection from antiretroviral treatment, the newness of the vaccine, mistrust of authorities and pharmaceutical companies and concerns regarding vaccine safety.

conclusionsMpox risk perception and vaccine acceptance were suboptimal. Vaccine acceptance was influenced by sociodemographic, perceived susceptibility and health behaviour-related factors. Targeted risk communication will enhance acceptance of mpox vaccination among people living with HIV in Nigeria.

Indexed as

AIDS VaccinesHealth Knowledge, Attitudes, PracticeHIV InfectionsPatient Acceptance of Health CareAdolescentAdultFemaleHumansLogistic ModelsMaleMiddle AgedMpox, MonkeypoxNigeriaSmallpox VaccineSurveys and QuestionnairesYoung AdultAIDS VaccinesSmallpox VaccinempoxNigeriapeople living with HIVrisk perceptionvaccine acceptance

Identifiers

PMID39731207
PMCPMC12050367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.